• Users Online: 73
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Archives Submit article Instructions Referee Resource Subscribe
ORIGINAL ARTICLE
Year : 2021  |  Volume : 8  |  Issue : 1  |  Page : 83-91

A prospective randomized comparative study between transdermal estradiol gel and oral estradiol valerate tablets for successful clinical outcome in frozen-thawed embryo transfer cycles


Department of Reproductive Medicine, Akanksha IVF Centre, Mata Chanan Devi Hospital, Janakpuri, New Delhi, India

Correspondence Address:
Dr. Jaya Kumari
Room no. 711, Department of Reproductive Medicine, Akanksha IVF Centre, Mata Chanan Devi Hospital, Block C-1, Janakpuri, New Delhi
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


Rights and PermissionsRights and Permissions

Background: The aim of this study was to evaluate the use of transdermal estradiol gel and compare it with oral estradiol valerate tablets for the preparation of endometrium in frozen-thawed embryo transfer (FET) cycles. Methods: This prospective trial included 100 women undergoing FET cycles during study period and they were randomized into one of the two groups. Group 1 (n = 50) received oral estradiol valerate tablet and group 2 (n = 50) received transdermal estradiol gel from day 2 of menstrual cycle and endometrial thickness monitored with transvaginal ultrasonography. Primary outcome of this study was to compare clinical pregnancy rate (CPR) between the two groups. Secondary outcomes were implantation rates (IRs), CPRs, miscarriage rates (MRs), endometrial thickness at the start of progesterone, cycle cancellation rates, undesirable side effects, and patient satisfaction score. Statistical testing was performed with SPSS 17.0. Results: There was no clinically significant difference in biochemical pregnancy rate, CPR, IR, and MR between the two groups. Endometrial thickness on day of progesterone start was higher in group 2 as opposed to group 1 (9.81 ± 0.861 vs. 9.46 ± 0.830; P-value = 0.043) which was clinically significant. Almost 37.5% patients (n = 18) in group 1 had mild adverse effects when compared with only 12.76% (n=6) in gel group (group 2). Conclusion: We conclude that transdermal estradiol gel is equally efficacious as oral estrogen in hormone replacement FET cycles but with added advantage of better patient comfort and lesser side effects with transdermal gel.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed170    
    Printed6    
    Emailed0    
    PDF Downloaded12    
    Comments [Add]    

Recommend this journal